BRPI0407611A - anti-cancer agent comprising protein lk8 as an active ingredient - Google Patents

anti-cancer agent comprising protein lk8 as an active ingredient

Info

Publication number
BRPI0407611A
BRPI0407611A BRPI0407611-7A BRPI0407611A BRPI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A
Authority
BR
Brazil
Prior art keywords
protein
active ingredient
cancer agent
agent
cancer
Prior art date
Application number
BRPI0407611-7A
Other languages
Portuguese (pt)
Inventor
Hyunkyung Yu
Jang-Seong Kim
Jin-Hyung Ahn
Ho-Jeong Lee
Kwa-Yub Kang
Hyung-Kwon Lim
In-Hwan Lim
Sung Geun Kim
Hak Kyu Joo
Jihyun Lee
Yeup Yoon
Doo-Hong Park
Jung Hwan Park
Original Assignee
Mogam Biotech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotech Res Inst filed Critical Mogam Biotech Res Inst
Publication of BRPI0407611A publication Critical patent/BRPI0407611A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"AGENTE ANTI-CáNCER COMPREENDENDO PROTEINA LK8 COMO UM INGREDIENTE ATIVO". A presente invenção se refere a um agente anti-câncer compreendendo proteina LK8 como um ingrediente ativo. O agente anti-câncer da presente invenção é efetivo para reprimir crescimento e metástase de tumor maligno. Desse modo, o agente pode ser efetivamente usado não somente como repressor de metástase de câncer, mas também como agente terapêutico de tumor malígno primário."ANTI-CANCER AGENT UNDERSTANDING LK8 PROTEIN AS AN ACTIVE INGREDIENT". The present invention relates to an anti-cancer agent comprising LK8 protein as an active ingredient. The anti-cancer agent of the present invention is effective for suppressing malignant tumor growth and metastasis. Thus, the agent can be effectively used not only as a cancer metastasis repressor but also as a primary malignant tumor therapeutic agent.

BRPI0407611-7A 2003-02-20 2004-02-20 anti-cancer agent comprising protein lk8 as an active ingredient BRPI0407611A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030010797A KR100595364B1 (en) 2003-02-20 2003-02-20 Anticancer agent containing L8 protein as an active ingredient
PCT/KR2004/000357 WO2004073730A1 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Publications (1)

Publication Number Publication Date
BRPI0407611A true BRPI0407611A (en) 2006-02-14

Family

ID=36116045

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407611-7A BRPI0407611A (en) 2003-02-20 2004-02-20 anti-cancer agent comprising protein lk8 as an active ingredient

Country Status (9)

Country Link
EP (1) EP1608395A4 (en)
JP (1) JP2006518342A (en)
KR (1) KR100595364B1 (en)
CN (1) CN100546646C (en)
AU (1) AU2004212856B2 (en)
BR (1) BRPI0407611A (en)
CA (1) CA2516172A1 (en)
RU (1) RU2306147C2 (en)
WO (1) WO2004073730A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285277B2 (en) 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
AU2003292696A1 (en) 2002-12-26 2004-08-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
EP1713511B1 (en) * 2004-01-09 2011-11-09 Mogam Biotechnology Research Institute Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
MXPA06014206A (en) 2004-06-25 2007-02-14 Takeda Pharmaceutical Metastin derivatives and use thereof.
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (en) 2005-12-22 2013-02-21 Takeda Pharmaceutical Metastin derivatives and use thereof
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
KR100888022B1 (en) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion protein between immunoglobulin Fc and human apolipoprotein (a) kringle fragment L8 8Fc
FR2919064B1 (en) * 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF ASSAYING APOLIPOPROTEIN ALL FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919062B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING AMINOACYLASE 1 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919061B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919065B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD FOR DETERMINING APOLIPOPROTEIN AI FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
ES2565512T3 (en) 2007-07-19 2016-04-05 bioMérieux Test procedure for liver fatty acid binding protein, ACE and CA19-9 for in vitro diagnosis of colorectal cancer
FR2919063B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING LEUCOCYTE ELASTASE INHIBITOR FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919060B1 (en) 2007-07-19 2012-11-30 Biomerieux Sa METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2933773B1 (en) 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
WO2012067427A2 (en) * 2010-11-16 2012-05-24 재단법인 목암생명공학연구소 Pharmaceutical composition containing lk8 protein as an active ingredient for preventing or treating diabetic retinopathy or age-related macular degeneration
CN121712509A (en) 2023-05-04 2026-03-20 锐新医药公司 Combination therapy for RAS related diseases or conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU774759B2 (en) * 1999-09-15 2004-07-08 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor

Also Published As

Publication number Publication date
KR100595364B1 (en) 2006-07-03
CA2516172A1 (en) 2004-09-02
AU2004212856B2 (en) 2007-07-19
CN100546646C (en) 2009-10-07
JP2006518342A (en) 2006-08-10
RU2306147C2 (en) 2007-09-20
EP1608395A4 (en) 2007-10-31
RU2005129273A (en) 2006-03-10
CN1753685A (en) 2006-03-29
EP1608395A1 (en) 2005-12-28
WO2004073730A1 (en) 2004-09-02
AU2004212856A1 (en) 2004-09-02
KR20040075270A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
PA8588601A1 (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
BRPI0207961A8 (en) USE OF EPOTHYLONE AND CAPECITABIN ANALOGS TO MANUFACTURE DRUG TO TREAT SOLID CANCEROUS TUMORS AND KIT COMPRISING THE SAID COMPOUNDS.
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
MXPA05012573A (en) Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors.
DK1663242T3 (en) 2,4-Pyrimidinediamine compounds and use as antiproliferative agents
CU23208A3 (en) OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
PA8571001A1 (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
SE0101387D0 (en) Novel compounds
CL2011003346A1 (en) Compounds derived from 2,3-dihydro-5h- [1,3] thiazolo [3,2-a] pyrimidin-5-one, modulators of pi3k; pharmaceutical composition; and use to treat an immune-based disease, cancer, or lung disease in a patient.
BRPI0415525A (en) imidazole derivatives and their use as pharmaceutical agents
BRPI0418251B8 (en) phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them
UY28441A1 (en) QUINAZOLINE DERIVATIVES
DK1318992T3 (en) Imidazole derivatives as Raf kinase inhibitors
HN2004000232A (en) "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM."
ECSP003610A (en) PYRIMIDINE-2,4,6 METALOPROTEIN INHIBITING TRIONES
DE50310516D1 (en) Fredericamycin DERIVATIVES
EP1819227A4 (en) PHARMACEUTICAL FORMULATION OF DECITABINE
BRPI0410649A (en) substituted benzo (b) thiophene 3-aryloxy and 3-heteroaryloxy as therapeutic agents with pi3k activity
SE0100158D0 (en) Novel method and composition for local treatment of Meniere's disease and tinnitus
GB0121490D0 (en) Ciompounds
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
BR0209645A (en) Oxazole and furopyrimidines and their use as medicines
DE60142913D1 (en) DRUG SOLUTIONS CONTAIN MODAFINIL COMPOUNDS
BR0312294A (en) Arylcarbonyl piperazines and hteroarylcarbonylpiperazines and their use to treat benign and malignant diseases
NI200300045A (en) INHIBITORS OF TRIARILOXIARILOXIPIRIMIDIN-2,4,6-METALOPROTEINASE TRION.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]